PPARγ and atherosclerosis

Current Medical Research and Opinion, Supplement

Volumn 21, Issue 1, 2005, Pages

  Staels, B ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Atherosclerosis; Cardiovascular disease; Diabetes; Glitazone; Peroxisome proliferator activated receptor ; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; GLIBENCLAMIDE; GLICLAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; L 805645; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; SIMVASTATIN; TROGLITAZONE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VOGLIBOSE; CARDIOVASCULAR AGENT; FIBRINOLYTIC AGENT;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; DRUG EFFECT; FOAM CELL; HEART PROTECTION; HUMAN; LEUKOCYTE ROLLING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM; ANIMAL; ANIMAL MODEL; ARTERIOSCLEROSIS; DIABETIC ANGIOPATHY; DRUG POTENTIATION; PHYSIOLOGY;

ANIMALS; ARTERIOSCLEROSIS; CARDIOVASCULAR AGENTS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FIBRINOLYTIC AGENTS; HUMANS; MODELS, ANIMAL; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 16844378797     PISSN: 01419951     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X36440     Document Type: Review

References (75)

1. Elbrecht A, Chen Y, Cullinan CA, et al. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun 1996;224:431-7
2. Spiegelman BM. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-14
3. Stumvoll M, Häring H-U. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002;34:217-24
4. Chinetti G, Fruchart J-C, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000;49:497-505
5. Marx N, Duez H, Fruchart J-C, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004;94:1168-78
6. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA 2002;287:2570-81
7. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34
8. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43
9. Rohde LE, Lee RT. Pathophysiology of atherosclerotic plaque development and rupture: an overview. Semin Vasc Med 2003;3:347-54
10. Ross R. Atherosclerosis is an inflammatory disease. N Engl J Med 1999;340:115-26
11. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004;109:III27-32
12. Cominacini L, Fratta Pasini A, Garbin U, et al. Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia 1995;38:1122-4
13. Cominacini L, Garbin U, Fratta Pasini A, et al. Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Rad Biol Med 1997;22:117-7
14. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004;291:1978-86
15. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000;101:235-8
16. Sidhu JS, Cowan D, Kaski JC. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am, J Cardiol 2004;94:151-6
17. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferators-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. Am Coll Cardiol 2003;42:1757-63
18. Cominacini L, Garbin U, Fratta Pasini A, et al. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes 1998;47:130-3
19. Caballero AE, Saouaf R, Lim SC, et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 2003;52:173-80
20. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003;26:2493-9
21. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84
22. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-35
23. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2004;93:362-5
24. Cardillo C, Nambi SS, Kilcoyne CM, et al. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation 1999;100:820-5
25. Donatelli M, Colletti I, Bucalo ML, Russo V, Verga S. Plasma endothelin levels in NIDDM patients with macroangiopathy. Diabetes Res 1994;25:159-64
26. Morise T, Takeuchi Y, Kawano M, Koni I, Takeda R. Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care 1995;18:87-9
27. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 2002;106:1783-7
28. Mather KJ, Mirzamohammadi B, Ltief A, Steinberg HO, Baron AD. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 2002;51:3517-23
29. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002;51:1157-65
30. Nakamura T, Ushiyama C, Suzuki S, et al. Comparative effects of pioglitazone, glibenclamide and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complic 2000;14:250-4
31. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase and MAP kinase-mediated signalling in human muscle. J Clin Invest 2000;105:311-20
32. Montagnani M, Golovchenko I, Kim I, et al. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 2002;277:1794-9
33. Delerive P, Martin-Nizard F, Chinetti G, et al. Peroxisome proliferator-activator receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein signalling pathway. Cir Res 1999;85:394-402
34. Martin-Nizard F, Furman C, Delerive P, et al. Peroxisome proliferator-activator receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells by inhibiting the activator protein signalling pathway. J Cardivasc Pharmacol 2002;40:822-31
35. Maxwell AJ, Cooke JP. The role of nitric oxide in atherosclerosis. Coron Arter Dis 1999;10:277-86
36. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:52-7
37. Cho D-H, Choi YJ, Jo SA, Jo I. Nitric oxide production and regulation of endothelial nitric oxide synthase phosophorylation by prolonged treatment with troglitazone. J Biol Chem 2004;279:2499-506
38. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD. PPARγ agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 2004;43:661-6
39. Dandona P, Mohanty P, Aljada A, et al. Inflammatory effect of rosiglitazone in mononuclear cells. Diabetologia 2001;44(Suppl. 1):A36 [Abstract A316]
40. Garg R, Kumbkarni Y, Aljada A, et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 2000;36:430-5
41. Suzuki M, Takamisawa I, Suzuki A, et al. Close association between insulin resistance and vascular dysfunction in subjects with type 2 diabetes and improvement by pioglitazone. Diabetes 2002;51:A304 [Abstract 1240-P]
42. Murao K, Imachi H, Momoi A, et al. Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett 1999;454:27-30
43. Jackson SM, Parhami F, Xi XP, et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 1999;19:2094-104
44. Wang P, Anderson PO, Chen S, Paulsson JM, Sjogren HO, Li S. Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands. Int Immunopharmacol 2001;1:803-12
45. Schönbeck U, Libby P. CD40 signalling and plaque instability. Circ Res 2001;89:1092-103
46. Varo N, Vicent D, Libby P, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients. Circulation 2003;107:2664-9
47. Assmann G, Schulte H. The prospective cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. American Heart Journal 1988;116:1713-24
48. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997;272:20963-6
49. Gardner CD, Fortmann SP, Krauss RM. Association of small, low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996;276:875-81
50. Cominacini L, Garbin U, Pastorino AM, et al. Increased susceptibility of LDL to in vitro oxidation in patients with insulin-dependent and non-insulin-dependent diabetes mellitus. Diabetes Res 1994;26:173-84
51. Gbaguidi FG, Chinetti G, Milosavljevic D, et al. Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages. FEBS Lett 2002;512:85-90
52. Haraguchi G, Kobayashi Y, Brown ML, et al. PPAR alpha and PPAR gamma activators suppress the monocyte-macrophage apoB-48 receptor. J Lipid Res 2003;44:1224-31
53. Chinetti G, Lestavel S, Bocher V, et al. PPAR-α and PPAR-γ induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001;7:53-8
54. Liang C-P, Han S, Okamoto H, et al. Increased CD36 protein as a response to defective insulin signaling in macrophages. J Clin Invest 2004;133:764-73
55. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22:1395-1409
56. Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JPD. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 2004;27:41-6
57. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE, Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001;12:413-23
58. Winkler K, Freedrich I, Baumstark MW, Wieland H, März W. Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus. Br J Diabetes Vasc Dis 2002;2:143-8
59. Tack CJJ, Smith P, Demacker PNM, Stalenhoef AEH. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998;21:796-9
60. Sunayama S, Wantanabe Y, Ohmura H, et al. Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis 1999;146:187-93
61. Hirano T, Yoshino G, Kazumi T. Troglitazone and small low-density lipoprotein in type 2 diabetes. Ann Intern Med 1998;129:162-3
62. Goetze S, Xi XP, Kawano H, et al. PPAR γ-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol 1999;33:798-806
63. Yoshimoto T, Naruse M, Shizu H. Vasculo-protective effects of insulin sensitising agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis 1999;145:333-40
64. Bruemmer D, Berger JP, Liu J, et al. A non-thiazolidinedione partial peroxisome proliferator-activated receptor γligand inhibits vascular smooth muscle cell growth. Eur J Pharmacol 2003;466:225-34
65. Bruemmer D, Yin F, Liu J, et al. Regulation of the growth arrest and DNA-damage-inducible gene 45 (GAD45) by peroxisome proliferator-activated receptor γ in vascular smooth muscle cell growth. Circ Res 2003;93:e38-47
66. De-Dios ST, Bruemmer D, Dilley RJ, et al. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-γ ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 2003;107:2548-50
67. Minamikawa J, Tanaka S, Yamauchi, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998;83:1818-20
68. Igarashi M, Hirata A, Yamaguchi H. Characterization of an inhibitory effect of pioglitazone in balloon-injured vascular smooth muscle cell growth. Metabolism 2001;50:955-62
69. Takagi T, Akasaka T, Yamamuro A, et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus. J Am Coll Cardiol 2000;36:1529-35
70. Takagi T, Yamamuro A, Tamita K, et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003;146:e5
71. Choi D, Kim S-K, Choi S-H, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004;27:2654-60
72. Osman A, Otero J, Brizolara A, et al. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J 2004;147:e23
73. Marx N, Skhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPAR-gamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPAR-gamma) expression and reduction of MMP-9 activity through PPAR-gamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998;153:17-23
74. Corti R, Osende J, Fallon JT, et al. The selective peroxismal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis. J Am Coll Cardiol 2004;43:464-73
75. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A. The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004;27:1647-53